<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00707590</url>
  </required_header>
  <id_info>
    <org_study_id>MB116-001</org_study_id>
    <nct_id>NCT00707590</nct_id>
  </id_info>
  <brief_title>Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability and the PK/PD relationship of BMS-767778 administered
      as single and multiple oral doses in healthy subjects, and in subjects with T2DM
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs, vital signs, ECG and clinical laboratory test results</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single and multiple dose (14 days) PK</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DPP-4 inhibition and incretin response</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: BMS-767778, Oral Solution, Oral, 1 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day
B: BMS-767778, Oral Solution, Oral, 3 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day
C: BMS-767778, Capsules, Oral, 10 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day
D: BMS-767778, Capsules, Oral, 30 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day
E: BMS-767778, Capsules, Oral, 100 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day
F: BMS-767778, Capsules, Oral, 300 mg, once daily, 2 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 2 days
G: BMS-767778, Capsules, Oral, 600 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: BMS-767778, Capsules, Oral, 10 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days
B: BMS-767778, Capsules, Oral, 30 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days
C: BMS-767778, Capsules, Oral, 100 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days
D: BMS-767778, Capsules, Oral, 300 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days
E: BMS-767778, Capsules, Oral, 600 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days
B: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-767778 or Placebo</intervention_name>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Parts A and Part B of the study (maximum age 45 years):

        Inclusion Criteria:

          -  Healthy male and female subjects as determined by medical history, physical
             examination, 12-lead electrocardiogram (ECG), and clinical laboratory evaluations will
             be eligible to participate in the study.

          -  Men and women who are not of childbearing potential (i.e., who are postmenopausal or
             surgically sterile)

        Exclusion Criteria:

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG or clinical laboratory determinations

        Part C of the study (maximum age 65 years):

        Inclusion criteria:

          -  Drug naive patients with T2DM or patients who are on metformin-monotherapy (at current
             dose for â‰¥ 8 weeks) with inadequately controlled blood glucose levels (HbA1c &gt;7 %and
             &lt;10 %) Men and women who are not of childbearing potential (i.e., who are
             postmenopausal or surgically sterile)

        Exclusion criteria:

          -  Poorly controlled diabetes with either new onset or worsening of symptoms of polyuria
             and polydipsia, weight loss, fatigue, abdominal pain, or other significant signs and
             symptoms

          -  Any of the following medical conditions: uncontrolled hypertension, unstable angina
             pectora, Cushing's syndrome, Addison's disease, uncontrolled hyperthyroidism or
             hypothyroidism, significant liver disease or renal failure, malignant diseases, or
             immunodeficiency (e.g., HIV/AIDS or organ-transplant), or history of myocardial
             infarction, congestive heart failure defined as New York Heart Association (NYHA)
             stage II and above, significant valvular disease, cardiac arrhythmia, or transient
             ischemic attack or cerebrovascular accidents (occurred within 6 months prior to entry
             into the study), or family history of Long QT Syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Quebec</city>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2008</study_first_submitted>
  <study_first_submitted_qc>June 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2008</study_first_posted>
  <last_update_submitted>February 9, 2009</last_update_submitted>
  <last_update_submitted_qc>February 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

